Hong Kong Infrastructure Stock News

In early December 2025, Bank of China Limited confirmed that Executive Vice President Liu Chenggang began concurrently serving as Secretary to the Board and Company Secretary, supported by a three-year waiver from strict Hong Kong listing rule requirements, with Joint Company Secretary Liu Lele assisting to ensure compliance. This appointment highlights the bank’s focus on aligning board-level governance with extensive internal experience, while relying on transitional regulatory waivers to...

Country Garden Services Holdings (SEHK:6098) just reshuffled its finance leadership, with long time executive Huang Peng stepping down as CFO to focus on incubation businesses and capital markets specialist Tian Tian stepping into the role. See our latest analysis for Country Garden Services Holdings. The reshuffle comes after a choppy stretch for the stock, with the latest share price at HK$6.37, a 1 day share price return of 1.92 percent but a 90 day share price return of negative 9.26...

Premium milestone reshapes the investment backdrop China Life Insurance (SEHK:2628) just crossed RMB700 billion in gross written premiums by the end of November 2025, a milestone that refines the stock’s appeal for investors focused on long term growth and income. See our latest analysis for China Life Insurance. The milestone is landing on a stock that already has strong momentum, with a roughly 21.8% 90 day share price return and a powerful year to date share price surge that backs up the...

In the last year, multiple insiders have substantially increased their holdings of Sino Biopharmaceutical Limited...

Key Insights Using the 2 Stage Free Cash Flow to Equity, AAC Technologies Holdings fair value estimate is HK$46.11 With...

Zhaojin Mining Industry Company Limited's ( HKG:1818 ) price-to-earnings (or "P/E") ratio of 39x might make it look...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

CSSC Offshore & Marine Engineering (Group) Company Limited ( HKG:317 ), might not be a large cap stock, but it received...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

There wouldn't be many who think Pa Shun International Holdings Limited's ( HKG:574 ) price-to-sales (or "P/S") ratio...

Jacobson Pharma (SEHK:2633) has posted a steady H1 2026 result, with revenue of HK$766.6 million and basic EPS of HK$0.071, supported by trailing 12 month revenue of about HK$1.5 billion and EPS of HK$0.152 that reflects solid earnings momentum over the past year. The company has seen revenue hover around the HK$1.5 billion mark over recent periods while EPS has increased from HK$0.129 to around HK$0.152 on a trailing basis, pointing to tighter execution and firmer margins that give investors...

Sa Sa International Holdings (SEHK:178) has just posted its H1 2026 numbers, with revenue coming in at HK$2.0 billion and basic EPS at HK$0.017, giving investors a fresh data point on the retailer’s post reopening trajectory. The company has seen revenue move from HK$1.9 billion in H1 2025 to HK$2.0 billion in H1 2026, while basic EPS has edged from HK$0.015 to HK$0.017 over the same period. This sets the stage for a debate about how durable its improving profitability really is as margins...

Luye Pharma Group (SEHK:2186) just wrapped up a financing move through its subsidiary, issuing 1,500,000 exchangeable preference shares tied to Boan Biotech’s stock, effectively tightening its grip on the biotech side of the business. See our latest analysis for Luye Pharma Group. The latest exchangeable preference share issuance comes after a year in which Luye Pharma’s 38.68% year to date share price return contrasts with a still negative 5 year total shareholder return of 21.81%. This...

Precision Tsugami China (SEHK:1651) has posted another busy half, with H1 2026 revenue coming in at about CNY 2.5 billion and basic EPS at CNY 1.36, setting the tone for a solid first leg of the fiscal year. The company has seen revenue climb from CNY 2,283.5 million in H2 2025 and CNY 1,978.1 million in H1 2025 to CNY 2,496.9 million in H1 2026, while basic EPS moved from CNY 0.90 in H1 2025 and CNY 1.18 in H2 2025 to CNY 1.36 in the latest half, with trailing twelve month net income...

Oriental Enterprise Holdings (SEHK:18) has posted a subdued set of H1 2026 numbers, with revenue of HK$248.4 million and net income of HK$1.3 million translating to basic EPS of HK$0.000534, while trailing 12 month revenue sits at HK$524.1 million and net income at HK$28.6 million with EPS of HK$0.011934. The company has seen revenue move from HK$291.1 million in H1 2025 to HK$248.4 million in H1 2026 and net income shift from HK$25.1 million to HK$1.3 million over the same periods. This sets...

JBM (Healthcare) (SEHK:2161) has reported H1 2026 revenue of HK$429.6 million with basic EPS of HK$0.141, building on a twelve month track where earnings grew 32% and five year EPS growth averaged 53.2% per year. Over recent periods the company has seen revenue move from HK$720.5 million to HK$812.98 million on a trailing twelve month basis, while net income excluding extra items rose from HK$163.9 million to HK$216.4 million. This sets up this half year print against a backdrop of improving...

China Gas Holdings Limited recently entered into a comprehensive cooperation agreement with EVE Energy Co., Ltd., aiming to jointly advance energy storage technology, biomass applications, and green, low‑carbon energy solutions across domestic and overseas markets while supporting China’s “Dual Carbon” goals. A distinctive feature of this partnership is the planned order of 1 GWh of battery cells or DC-side storage products within one year, tying long-term technology collaboration directly...

If you are wondering whether China Unicom (Hong Kong) still offers good value after a strong multi year run, or if most of the upside is already priced in, this article is for you. The share price has pulled back recently, down 3.3% over the last week and 12.3% over the last month, but it is still up 19.1% year to date, 34.0% over 1 year, 123.3% over 3 years and 164.2% over 5 years. That kind of long term outperformance has been underpinned by Beijing's ongoing push for state owned telecoms...

MMG (SEHK:1208) just rolled out a sweeping leadership reshuffle, with CAO Liang taking over as chairman and new presidents appointed for Las Bambas and Africa. For investors, this is really about future strategy and execution. See our latest analysis for MMG. The shake up comes after a powerful run in the shares, with MMG’s 1 month share price return of 19.10% and 3 month share price return of 45.70% adding to an already substantial year to date share price return of 237.85%. The 1 year total...

At its extraordinary general meeting on 12 December 2025, AviChina Industry & Technology approved amendments to its Articles of Association, including abolishing the Supervisory Committee system, and confirmed the appointment of Mr. Gao Jiming as a non-executive director through 2027. This governance overhaul reduces one layer of oversight while reshaping the board, raising fresh questions about how management will now be monitored. We will now examine how the abolition of the Supervisory...

If you have been wondering whether Semiconductor Manufacturing International is still a smart buy after its huge run up, you are not alone. This stock has become a lightning rod for debates about value versus momentum. Despite a recent pullback of around 2.9% over the last week and 7.6% over the last month, the shares are still up an eye catching 133.4% year to date and about 161.4% over the past year, which naturally raises questions about how much upside might be left. These moves have...

If you are wondering whether Ascentage Pharma Group International is still a smart way to get exposure to biotech upside, you are not alone. That is exactly what we are going to unpack here. Despite a choppy recent stretch, with the share price down 6.8% over the last week and 8.1% over the past month, the stock is still sitting on gains of 35.4% year to date and 53.1% over the last year, building on a 131.9% return over three years. Recent moves have been shaped less by day to day trading...

In the past week, InnoCare Pharma reported China NMPA approval of zurletrectinib (ICP-723) for NTRK fusion-positive solid tumors in patients aged 12 and above, alongside strong efficacy and safety data, while also showcasing extensive positive clinical results for orelabrutinib and mesutoclax at the ASH 67th Annual Meeting. This marks InnoCare’s first approved solid-tumor therapy, adding a blood–brain-barrier-penetrant TRK inhibitor to its portfolio and underscoring its push to build a broad...

CStone Pharmaceuticals announced that its RET-targeted cancer therapy GAVRETO® (pralsetinib) has been approved for inclusion in China’s National Reimbursement Drug List, with reimbursement due to begin on 1 January 2026. This listing materially broadens patient access in China’s public healthcare system, potentially reinforcing CStone’s role as a key oncology player in Greater China. We’ll now examine how NRDL inclusion for GAVRETO shapes CStone’s investment narrative, particularly around...